Immortalized canine dystrophic myoblast cell lines for development of peptide-conjugated splice-switching oligonucleotides

Immortalized canine dystrophic myoblast cell lines for development of peptide-conjugated splice-switching oligonucleotides

Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disease caused by frameshift or nonsense mutations in the <i>DMD</i> gene, resulting in the loss of dystrophin from muscle membranes. Exon skipping using splice-switching oligonucleotides (SSOs) restores the reading frame of &l...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Tone, Y, Mamchaoui, K, Tsoumpra, MK, Hashimoto, Y, Terada, R, Maruyama, R, Gait, MJ, Arzumanov, AA, McClorey, G, Imamura, M, Takeda, S, Yokota, T, Wood, MJA, Mouly, V, Aoki, Y
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Mary Ann Liebert 2021

Παρόμοια τεκμήρια

Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
ανά: Gait, M, κ.ά.
Έκδοση: (2018)

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
ανά: James S. Novak, κ.ά.
Έκδοση: (2017-10-01)

Cell-penetrating peptides to enhance delivery of Oligonucleotide-based therapeutics
ανά: McClorey, G, κ.ά.
Έκδοση: (2018)

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
ανά: James S. Novak, κ.ά.
Έκδοση: (2018-03-01)

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
ανά: James S. Novak, κ.ά.
Έκδοση: (2018-01-01)

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
ανά: Tsoumpra, MK, κ.ά.
Έκδοση: (2019)

Profile of circadianly regulated metabolic genes in dystrophic heart
ανά: Betts, C, κ.ά.
Έκδοση: (2018)

A functional human motor unit platform engineered from human embryonic stem cells and immortalized skeletal myoblasts
ανά: Abd Al Samid M, κ.ά.
Έκδοση: (2018-11-01)

Emerging oligonucleotide therapeutics for rare neuromuscular diseases
ανά: Aoki, Y, κ.ά.
Έκδοση: (2021)

Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders
ανά: Mamchaoui Kamel, κ.ά.
Έκδοση: (2011-11-01)

Covalently attached intercalators restore duplex stability and splice-switching activity to triazole-modified oligonucleotides
ανά: Dysko, A, κ.ά.
Έκδοση: (2022)

Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient
ανά: Saito, T, κ.ά.
Έκδοση: (2010)

Design and application of bispecific splice-switching oligonucleotides.
ανά: Bestas, B, κ.ά.
Έκδοση: (2014)

Inhibiting Myostatin with Follistatin Improves the Success of Myoblast Transplantation in Dystrophic Mice
ανά: Basma F. Benabdallah, κ.ά.
Έκδοση: (2008-03-01)

Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
ανά: Yokota, T, κ.ά.
Έκδοση: (2012)

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology
ανά: Van Westering, T, κ.ά.
Έκδοση: (2019)

Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
ανά: Aoki, Y, κ.ά.
Έκδοση: (2012)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides.
ανά: Marcel Veltrop, κ.ά.
Έκδοση: (2018-01-01)

Cellular and Genomic Features of Muscle Differentiation from Isogenic Fibroblasts and Myoblasts
ανά: Louise Benarroch, κ.ά.
Έκδοση: (2023-08-01)

New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy.
ανά: Aoki, Y, κ.ά.
Έκδοση: (2012)

NOVEL CELL PENETRATING PEPTIDES FOR SKELETAL AND CARDIAC MUSCLE DELIVERY OF PMO ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
ανά: Hammond, S, κ.ά.
Έκδοση: (2011)

Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
ανά: Yin, H, κ.ά.
Έκδοση: (2011)

Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice
ανά: Yin, H, κ.ά.
Έκδοση: (2011)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
ανά: Aoki, Y, κ.ά.
Έκδοση: (2011)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.
ανά: Betts, C, κ.ά.
Έκδοση: (2012)

Administration of a Soluble Activin Type IIB Receptor Promotes the Transplantation of Human Myoblasts in Dystrophic Mice
ανά: Raouia Fakhfakh, κ.ά.
Έκδοση: (2012-07-01)

Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology
ανά: Aurelien Lathuiliere, κ.ά.
Έκδοση: (2023-12-01)

Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology
ανά: Aurelien Lathuiliere, κ.ά.
Έκδοση: (2022-09-01)

Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System
ανά: Annalisa Lattanzi, κ.ά.
Έκδοση: (2017-06-01)

Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD
ανά: Godfrey, C, κ.ά.
Έκδοση: (2012)

An LNA-amide modification that enhances the cell uptake and activity of phosphorothioate exon-skipping oligonucleotides
ανά: Baker, YR, κ.ά.
Έκδοση: (2022)

Development of LNA gapmer oligonucleotide-based therapy for ALS/FTD caused by the C9orf72 repeat expansion
ανά: Sathyaprakash, C, κ.ά.
Έκδοση: (2020)

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
ανά: Klein, AF, κ.ά.
Έκδοση: (2019)

Advances in oligonucleotide drug delivery
ανά: Roberts, TC, κ.ά.
Έκδοση: (2020)

Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient.
ανά: Takashi Saito, κ.ά.
Έκδοση: (2010-01-01)

Early signs of architectural and biomechanical failure in isolated myofibers and immortalized myoblasts from desmin-mutant knock-in mice
ανά: Stefanie Diermeier, κ.ά.
Έκδοση: (2017-05-01)

In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy.
ανά: Yusuke Echigoya, κ.ά.
Έκδοση: (2015-01-01)

Diaphragm rescue alone prevents heart dysfunction in dystrophic mice.
ανά: Crisp, A, κ.ά.
Έκδοση: (2011)

Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa
ανά: Jeroen Bremer, κ.ά.
Έκδοση: (2016-01-01)

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology
ανά: Tirsa L.E. vanWestering, κ.ά.
Έκδοση: (2020-04-01)